Evaluation of gingival crevicular fluid levels of tissue plasminogen activator, plasminogen activator inhibitor 2, matrix metalloproteinase-3 and interleukin 1-β in patients with different periodontal diseases

Journal of Periodontal Research

Volumn 50, Issue 1, 2015, Pages 44-51

  Toyman, U ^a,b   Tuter G ^a   Kurtis B ^a   Kivrak, E ^a   Bozkurt, Ş ^c   Yucel A A ^d   Serdar, M ^e,f  

^a GAZI UNIVERSITY   (Turkey)

^b The Health Ministry Center of Oral and Dental Health   (Turkey)

^c ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^d GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^e GULHANE SCHOOL OF MEDICINE   (Turkey)

^f ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Interleukin 1beta; Matrix metalloproteinase 3; Plasminogen activator inhibitor 2; Tissue plasminogen activator

Indexed keywords

FIBRINOLYTIC AGENT; INTERLEUKIN 1BETA; MMP3 PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITOR; STROMELYSIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGGRESSIVE PERIODONTITIS; CHEMISTRY; CHRONIC PERIODONTITIS; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; GINGIVITIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PERIODONTAL DISEASE; PERIODONTAL POCKET; PERIODONTICS; TOOTH PLAQUE; YOUNG ADULT;

ADULT; AGGRESSIVE PERIODONTITIS; CHRONIC PERIODONTITIS; DENTAL PLAQUE INDEX; FEMALE; FIBRINOLYTIC AGENTS; GINGIVAL CREVICULAR FLUID; HUMANS; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL INDEX; PERIODONTAL POCKET; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITORS; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84920830619     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12179     Document Type: Article

References (44)

1. Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin Microbiol Rev 2001;14:727-752, table of contents.
2. Sahingur SE, Cohen RE. Analysis of host responses and risk for disease progression. Periodontol 2000 2004;34:57-83.
3. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-262.
4. Domeij H, Yucel-Lindberg T, Modeer T. Signal pathways involved in the production of MMP-1 and MMP-3 in human gingival fibroblasts. Eur J Oral Sci 2002;110:302-306.
5. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
6. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
7. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121-131.
8. Kinnby B, Matsson L, Astedt B. Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid. J Periodont Res 1996;31:271-277.
9. Kucharewicz I, Kowal K, Buczko W, Bodzenta-Lukaszyk A. The plasmin system in airway remodeling. Thromb Res 2003;112:1-7.
10. Tuter G, Ozdemir B, Kurtis B, Serdar M, Yucel AA, Ayhan E. Short term effects of non-surgical periodontal treatment on gingival crevicular fluid levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2 (PAI-2) in patients with chronic and aggressive periodontitis. Arch Oral Biol 2013;58:391-396.
11. Zhang L, Seiffert D, Fowler BJ et al. Plasminogen has a broad extrahepatic distribution. Thromb Haemost 2002;87:493-501.
12. Sulniute R, Lindh T, Wilczynska M, Li J, Ny T. Plasmin is essential in preventing periodontitis in mice. Am J Pathol 2011;179:819-828.
13. Arnout J, Hoylaerts MF, Lijnen HR. Haemostasis. Handb Exp Pharmacol 2006;176:1-41.
14. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995;86:4007-4024.
15. Yin X, Bunn CL, Bartold PM. Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2(PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients. J Clin Periodontol 2000;27:149-156.
16. Kinnby B, Borgstrom MK, Granath L, Lecander I, Sundin B. Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival fluid from 8-9-year-old children. Scand J Dent Res 1993;101:279-281.
17. Kinnby B, Matsson L, Lecander I. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis. Scand J Dent Res 1994;102:334-341.
18. Kinnby B. The plasminogen activating system in periodontal health and disease. Biol Chem 2002;383:85-92.
19. Kinnby CG, Palm L, Widenheim J. Evaluation of information on dental health care at child health centers. Differences in educational level, attitudes, and knowledge among parents of preschool children with different caries experience. Acta Odontol Scand 1991;49:289-295.
20. Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontol 2000 2000;24:226-238.
21. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992;267:3581-3584.
22. Alpagot T, Bell C, Lundergan W, Chambers DW, Rudin R. Longitudinal evaluation of GCF MMP-3 and TIMP-1 levels as prognostic factors for progression of periodontitis. J Clin Periodontol 2001;28:353-359.
23. Tuter G, Kurtis B, Serdar M et al. Effects of phase I periodontal treatment on gingival crevicular fluid levels of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1. J Clin Periodontol 2005;32:1011-1015.
24. Zhao XQ, Meng S, Wu YF, Chen Y, Ge S. [Expression of MMP-2 and MMP-3 in periodontal tissues of rat periodontitis model]. Hua Xi Kou Qiang Yi Xue Za Zhi 2006;24:202-205.
25. Jenkins K, Javadi M, Borghaei RC. Interleukin-4 suppresses IL-1-induced expression of matrix metalloproteinase-3 in human gingival fibroblasts. J Periodontol 2004;75:283-291.
26. Andriamanalijaona R, Benateau H, Barre PE et al. Effect of interleukin-1beta on transforming growth factor-beta and bone morphogenetic protein-2 expression in human periodontal ligament and alveolar bone cells in culture: modulation by avocado and soybean unsaponifiables. J Periodontol 2006;77:1156-1166.
27. Nakaya H, Oates TW, Hoang AM, Kamoi K, Cochran DL. Effects of interleukin-1 beta on matrix metalloproteinase-3 levels in human periodontal ligament cells. J Periodontol 1997;68:517-523.
28. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
29. Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
30. Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533-551.
31. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000;71:1535-1545.
32. Akcali A, Huck O, Tenenbaum H, Davideau JL, Buduneli N. Periodontal diseases and stress: a brief review. J Oral Rehabil 2013;40:60-68.
33. Ozdemir SP, Kurtis B, Tuter G et al. Effects of low-dose doxycycline and bisphosphonate clodronate on alveolar bone loss and gingival levels of matrix metalloproteinase-9 and interleukin-1beta in rats with diabetes: a histomorphometric and immunohistochemical study. J Periodontol 2012;83:1172-1182.
34. Delaleu N, Bickel M. Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation. Periodontol 2000 2004;35:42-52.
35. Beklen A, Ainola M, Hukkanen M, Gurgan C, Sorsa T, Konttinen YT. MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis. J Dent Res 2007;86:347-351.
36. Ruwanpura SM, Noguchi K, Ishikawa I. Prostaglandin E2 regulates interleukin-1beta-induced matrix metalloproteinase-3 production in human gingival fibroblasts. J Dent Res 2004;83:260-265.
37. Biyikoğlu B, Buduneli N, Kardesler L, Aksu K, Oder G, Kutukculer N. Evaluation of t-PA, PAI-2, IL-1beta and PGE(2) in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease. J Clin Periodontol 2006;33:605-611.
38. Kamio N, Hashizume H, Nakao S, Matsushima K, Sugiya H. IL-1beta stimulates urokinase-type plasminogen activator expression and secretion in human dental pulp cells. Biomed Res 2007;28:315-322.
39. Tuter G, Kurtis B, Serdar M. Interleukin-1beta and thiobarbituric acid reactive substance (TBARS) levels after phase I periodontal therapy in patients with chronic periodontitis. J Periodontol 2001;72:883-888.
40. Preiss DS, Meyle J. Interleukin-1 beta concentration of gingival crevicular fluid. J Periodontol 1994;65:423-428.
41. Suzuki M, Ishihara Y, Kamiya Y et al. Soluble interleukin-1 receptor type II levels in gingival crevicular fluid in aggressive and chronic periodontitis. J Periodontol 2008;79:495-500.
42. Syrovets T, Jendrach M, Rohwedder A, Schule A, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 2001;97:3941-3950.
43. Kardesler L, Buduneli N, Biyikoğlu B, Cetinkalp S, Kutukculer N. Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease. Clin Biochem 2008;41:863-868.
44. Xiao Y, Bunn CL, Bartold PM. Effect of lipopolysaccharide from periodontal pathogens on the production of tissue plasminogen activator and plasminogen activator inhibitor 2 by human gingival fibroblasts. J Periodont Res 2001;36:25-31.